胶质母细胞瘤的治疗现状

Current Status of Glioblastoma Treatment

摘要: 背景：胶质瘤是人类最常见的脑瘤。胶质母细胞瘤又称多形性胶质母细胞瘤(glioblastoma multiforme, GBM，简称胶母)是最常见、最具侵袭性的胶质瘤之一，占原发性脑肿瘤的52%，占所有颅内肿瘤的20%。在欧洲和北美，GBM的发病率为2~3/10万人。GBM患者预后较差，中位生存期(MS)保持在12~15个月之间，从诊断开始的5年生存率低于5%。GBM的标准治疗包括手术、放疗、化疗和综合治疗。然而，新诊断的GBM患者的MS在过去10年中只有轻微的改善。目的：对胶质母细胞瘤的最新治疗现状进行综述。方法：通过检索近几年PubMed数据库、中国知网等中英文期刊全文数据库相关内容文章，并系统整理相关重要文献进行综述。结果与结论：目前的治疗方法均不能彻底治愈GBM患者，只能延长其生存期。随着肿瘤基因层面的进展以及最佳联合治疗方式的进一步研究，GBM患者的预后将会更加光明。

Abstract: BACKGROUND: Glioma is the most common brain tumor in humans. Glioblastoma Multiforme (GBM) is one of the most common and aggressive gliomas, accounting for 52 percent of primary brain tumors and 20 percent of all intracranial tumors. In Europe and North America, the incidence of GBM is 2 - 3 per 100,000 people. GBM patients have a poor prognosis, the median survival (MS) remains between 12 - 15 months, and the 5-year survival rate from diagnosis is less than 5%. Standard treatment for GBM includes surgery, radiotherapy, chemotherapy, and combination therapy. However, MS in newly diagnosed GBM patients has improved only slightly in the past 10 years. OBJECTIVE: To review the latest treatment of glioblastoma. METHODS: By retrieving the articles related to the full-text databases of Chinese and English periodicals such as PubMed database and CNKI in recent years, and systematically sorting out the relevant important literatures for review. RESULTS AND CONCLUSION: Current treatment methods cannot completely cure GBM patients, only to prolong their survival. With the progress of tumor gene level and further research on the best combination therapy, the prognosis of GBM patients will be brighter.